Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.

Carroll FI.

Ann N Y Acad Sci. 2008 Oct;1141:221-32. doi: 10.1196/annals.1441.015. Review.

PMID:
18991960
2.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280
3.

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.

Hughes ZA, Neal SJ, Smith DL, Sukoff Rizzo SJ, Pulicicchio CM, Lotarski S, Lu S, Dwyer JM, Brennan J, Olsen M, Bender CN, Kouranova E, Andree TH, Harrison JE, Whiteside GT, Springer D, O'Neil SV, Leonard SK, Schechter LE, Dunlop J, Rosenzweig-Lipson S, Ring RH.

Neuropharmacology. 2013 Mar;66:202-14. doi: 10.1016/j.neuropharm.2012.04.007.

PMID:
22551786
4.

Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

Palucha A, Pilc A.

Pharmacol Ther. 2007 Jul;115(1):116-47. Review.

PMID:
17582504
5.

Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity.

Alagille D, Baldwin RM, Roth BL, Wroblewski JT, Grajkowska E, Tamagnan GD.

Bioorg Med Chem. 2005 Jan 3;13(1):197-209.

PMID:
15582465
6.

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.

Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S, Washburn M, Varney MA.

J Med Chem. 2003 Jan 16;46(2):204-6.

PMID:
12519057
7.

5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.

Roppe JR, Wang B, Huang D, Tehrani L, Kamenecka T, Schweiger EJ, Anderson JJ, Brodkin J, Jiang X, Cramer M, Chung J, Reyes-Manalo G, Munoz B, Cosford ND.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6.

PMID:
15225713
8.

Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Kew JN, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.

PMID:
15731895
9.

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr.

J Pharmacol Exp Ther. 2005 Apr;313(1):199-206.

11.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
12.

Reduced stress-induced hyperthermia in mGluR5 knockout mice.

Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA.

Eur J Neurosci. 2002 Dec;16(11):2241-4.

PMID:
12473093
13.

Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.

Roppe J, Smith ND, Huang D, Tehrani L, Wang B, Anderson J, Brodkin J, Chung J, Jiang X, King C, Munoz B, Varney MA, Prasit P, Cosford ND.

J Med Chem. 2004 Sep 9;47(19):4645-8.

PMID:
15341479
14.

Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure.

Ceccarelli SM, Jaeschke G, Buettelmann B, Huwyler J, Kolczewski S, Peters JU, Prinssen E, Porter R, Spooren W, Vieira E.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1302-6.

PMID:
17189691
15.

Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.

Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H.

J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118.

16.

Discovery of novel modulators of metabotropic glutamate receptor subtype-5.

Wang B, Vernier JM, Rao S, Chung J, Anderson JJ, Brodkin JD, Jiang X, Gardner MF, Yang X, Munoz B.

Bioorg Med Chem. 2004 Jan 2;12(1):17-21.

PMID:
14697765
17.

Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.

Kehne J, De Lombaert S.

Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):467-93. Review.

PMID:
12769601
18.

Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity.

Spanka C, Glatthar R, Desrayaud S, Fendt M, Orain D, Troxler T, Vranesic I.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):184-8. doi: 10.1016/j.bmcl.2009.11.001.

PMID:
19931453
19.

Recent progress in the development of allosteric modulators of mGluR5.

Rodriguez AL, Williams R.

Curr Opin Drug Discov Devel. 2007 Nov;10(6):715-22. Review.

PMID:
17987523
20.
Items per page

Supplemental Content

Support Center